Hartman Institute for Therapeutic Organ Regeneration

Heterogeneity of clonal expansion and maturation-linked mutation acquisition in hematopoietic progenitors in human acute myeloid leukemia.

TitleHeterogeneity of clonal expansion and maturation-linked mutation acquisition in hematopoietic progenitors in human acute myeloid leukemia.
Publication TypeJournal Article
Year of Publication2014
AuthorsWalter RB, Laszlo GS, Lionberger JM, Pollard JA, Harrington KH, Gudgeon CJ, Othus M, Rafii S, Meshinchi S, Appelbaum FR, Bernstein ID
JournalLeukemia
Volume28
Issue10
Pagination1969-77
Date Published2014 Oct
ISSN1476-5551
KeywordsAntigens, CD34, Cell Hypoxia, Cell Separation, Coculture Techniques, Core Binding Factors, Flow Cytometry, Hematopoietic Stem Cells, Hematopoietic System, Humans, Leukemia, Myeloid, Acute, Mutation, Prognosis, Receptors, Aryl Hydrocarbon, Sialic Acid Binding Ig-like Lectin 3
Abstract

<p>Recent technological advances led to an appreciation of the genetic complexity of human acute myeloid leukemia (AML), but underlying progenitor cells remain poorly understood because their rarity precludes direct study. We developed a co-culture method integrating hypoxia, aryl hydrocarbon receptor inhibition and micro-environmental support via human endothelial cells to isolate these cells. X-chromosome inactivation studies of the least mature precursors derived following prolonged culture of CD34(+)/CD33(-) cells revealed polyclonal growth in highly curable AMLs, suggesting that mutations necessary for clonal expansion were acquired in more mature progenitors. Consistently, in core-binding factor (CBF) leukemias with known complementing mutations, immature precursors derived following prolonged culture of CD34(+)/CD33(-) cells harbored neither mutation or the CBF mutation alone, whereas more mature precursors often carried both mutations. These results were in contrast to those with leukemias with poor prognosis that showed clonal dominance in the least mature precursors. These data indicate heterogeneity among progenitors in human AML that may have prognostic and therapeutic implications.</p>

DOI10.1038/leu.2014.107
Alternate JournalLeukemia
PubMed ID24721792
PubMed Central IDPMC4167978
Grant ListU10-CA32102 / CA / NCI NIH HHS / United States
P30-CA015704-35S6 / CA / NCI NIH HHS / United States
P30 CA015704 / CA / NCI NIH HHS / United States
U10-CA098453 / CA / NCI NIH HHS / United States
U10-CA38926 / CA / NCI NIH HHS / United States
U10 CA032102 / CA / NCI NIH HHS / United States
U10 CA038926 / CA / NCI NIH HHS / United States
U10 CA180888 / CA / NCI NIH HHS / United States
U10 CA180819 / CA / NCI NIH HHS / United States

Weill Cornell Medicine
Hartman Institute for Therapeutic Organ Regeneration
1300 York Ave, Box 136 New York, NY 10065